HomeCompareMRES vs KMB

MRES vs KMB: Dividend Comparison 2026

MRES yields 142857.14% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRES wins by $1.703105290929614e+28M in total portfolio value
10 years
MRES
MRES
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full MRES calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — MRES vs KMB

📍 MRES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRESKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRES + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRES pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRES
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, MRES beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRES + KMB for your $10,000?

MRES: 50%KMB: 50%
100% KMB50/50100% MRES
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

MRES
No analyst data
Altman Z
-24.2
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRES buys
0
KMB buys
0
No recent congressional trades found for MRES or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRESKMB
Forward yield142857.14%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$1.703105290929614e+28M$45.9K
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00$5,211.33
Total dividends collected$1.70295189426983e+28M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MRES vs KMB ($10,000, DRIP)

YearMRES PortfolioMRES Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$14,296,414$14,285,714.29$11,314$613.68+$14.29MMRES
2$19,102,632,658$19,087,335,494.95$12,865$759.19+$19102.62MMRES
3$23,856,124,353,624$23,835,684,536,679.88$14,709$943.96+$23856124.34MMRES
4$27,845,102,711,212,050$27,819,576,658,153,670.00$16,919$1,180.17+$27845102711.20MMRES
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$19,588$1,484.33+$30376787884694.17MMRES
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$22,838$1,879.06+$30972831647170752.00MMRES
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$26,832$2,395.60+$29516720240819920896.00MMRES
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$31,788$3,077.63+$2.6290911335300947e+22MMRES
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$38,000$3,986.82+$2.1887488081496375e+25MMRES
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$45,872$5,211.33+$1.703105290929614e+28MMRES

MRES vs KMB: Complete Analysis 2026

MRESStock

Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.

Full MRES Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this MRES vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRES vs SCHDMRES vs JEPIMRES vs OMRES vs KOMRES vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.